Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a 1,5-benzodiazepine with anticonvulsant properties. It is used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) and other seizure disorders.
## Primary Indications
* Adjunctive therapy for seizures in Lennox-Gastaut syndrome (LGS).
* Adjunctive therapy for other seizure types, including absence, myoclonic, and atonic seizures.
## Adult Dosing
* **LGS and other seizure types:**
* **Initiation:** 5 mg twice daily.
* **Titration:** Increase dose by 5 mg to 10 mg every week based on clinical response and tolerability.
* **Maintenance:** Typically 10 mg to 20 mg twice daily.
* **Maximum:** 20 mg twice daily (40 mg/day).
## Pediatric Dosing
* **LGS and other seizure types:**
* **Ages 2 to <10 years or weight <30 kg:**
* **Initiation:** 2.5 mg once daily.
* **Titration:** Increase dose by 2.5 mg to 5 mg every week based on clinical response and tolerability.
* **Maintenance:** Typically 5 mg twice daily.
* **Maximum:** 10 mg twice daily (20 mg/day).
* **Ages ≥10 years or weight ≥30 kg:**
* **Initiation:** 5 mg twice daily.
* **Titration:** Increase dose by 5 mg to 10 mg every week based on clinical response and tolerability.
* **Maintenance:** Typically 10 mg to 20 mg twice daily.
* **Maximum:** 20 mg twice daily (40 mg/day).
* **Note:** Dosing for children younger than 2 years is not well-established.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Dose reduction may be necessary. Specific recommendations are not well-defined.
* **Renal Impairment:** Use with caution. Dose reduction may be necessary. Specific recommendations are not well-defined.
## Contraindications
* Hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory insufficiency.
* Severe hepatic insufficiency.
* Sleep apnea syndrome.
## Adverse Effects
* **Common:** Somnolence, fatigue, increased salivation, constipation, decreased appetite, aggression, irritability, ataxia, dizziness, vomiting, rash.
* **Serious:** Serious skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), suicidal behavior or ideation, respiratory depression, dependence and withdrawal symptoms, paradoxical reactions (e.g., increased seizure frequency, agitation, hostility).
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other benzodiazepines, barbiturates):** Increased risk of sedation, respiratory depression, and coma.
* **CYP2C19 Inhibitors (e.g., fluconazole, omeprazole):** May increase clobazam concentrations.
* **CYP2C19 Inducers (e.g., rifampin):** May decrease clobazam concentrations.
* **Strong CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole):** May increase clobazam concentrations.
* **Antiepileptic Drugs (AEDs):** Potential for altered efficacy or increased adverse effects; monitor closely.
## Monitoring
* Monitor for effectiveness (seizure frequency).
* Monitor for adverse effects, especially somnolence, fatigue, ataxia, and behavioral changes.
* Monitor for signs of respiratory depression, particularly when used with other CNS depressants.
* Monitor for signs of withdrawal upon discontinuation.
* Monitor for suicidal behavior or ideation.
## Clinical Pearls
* Clobazam is a Schedule IV controlled substance.
* Taper discontinuation gradually to avoid withdrawal symptoms.
* May cause increased salivation and drooling; consider anticholinergic agents if problematic.
* Rash can be a sign of a serious skin reaction; discontinue immediately if observed.
* Sedation is a common dose-limiting side effect.
---
*Disclaimer: This information is intended for clinical use and does not replace a thorough review of the official prescribing information or local protocols. Always verify current drug information before administration.*
